New Immune-Targeting drug IMA402 enters human trials for Hard-to-Treat cancers
Disease control
Recruiting now
This early-stage trial tests a new drug, IMA402, designed to help the immune system attack cancer cells. It is for adults with solid tumors that have returned or not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors.
Phase: PHASE1, PHASE2 • Sponsor: Immatics Biotechnologies GmbH • Aim: Disease control
Last updated Jun 09, 2026 12:07 UTC